Can I Take St. John's Wort with Spironolactone?

Why the Interaction Matters: Spironolactone Basics

Spironolactone (Aldactone, CaroSpir) is an aldosterone antagonist approved for hypertension, edema, and heart failure at doses of 25-400 mg/day. Off-label, dermatologists and gynecologists prescribe it at 50-200 mg/day for hormonal acne and hirsutism, often in women with polycystic ovary syndrome (PCOS). At these lower doses, its primary mechanism shifts from sodium/water balance to androgen receptor blockade and reduction of sebum production.

How Spironolactone Is Metabolized

After oral ingestion, spironolactone undergoes rapid and extensive first-pass metabolism. Its two pharmacologically active metabolites, canrenone and 7-alpha-thiomethylspironolactone, are responsible for much of its clinical effect. The parent drug and metabolites are processed largely through CYP3A4 in the liver and intestinal wall, with some contribution from CYP2C8 [1].

Because a significant fraction of spironolactone is subject to first-pass CYP3A4 metabolism before it even reaches systemic circulation, any agent that upregulates this enzyme can meaningfully cut the drug's bioavailability. A 2014 review of aldosterone antagonist pharmacokinetics published in the British Journal of Clinical Pharmacology confirmed that CYP3A4 activity directly governs canrenone area-under-the-curve (AUC) [2].

Why Oral Bioavailability Is the Vulnerable Step

Spironolactone's oral bioavailability ranges from roughly 60-90% depending on formulation and food intake. That variability means the drug already sits in a window where enzyme induction has room to produce a clinically visible drop. For comparison, drugs with near-100% bioavailability lose relatively little ground when CYP3A4 is induced; spironolactone is not in that category.

What St. John's Wort Does to Drug-Metabolizing Enzymes

St. John's Wort (Hypericum perforatum) is one of the most widely used herbal supplements in the United States and Europe, purchased primarily for mild-to-moderate depression and mood support. The active constituent responsible for most drug interactions is hyperforin, a phloroglucinol compound present in standardized extracts at roughly 3-5% by weight.

The PXR-CYP3A4 Axis

Hyperforin binds the pregnane X receptor (PXR) with high affinity. PXR is a nuclear receptor that acts as the master regulator of CYP3A4 gene transcription. When hyperforin activates PXR, the receptor dimerizes with the retinoid X receptor and binds to response elements in the CYP3A4 promoter, driving sustained upregulation of CYP3A4 protein in hepatocytes and enterocytes [3].

A controlled crossover pharmacokinetic study published in Clinical Pharmacology and Therapeutics (Roby et al., 2000, N=12) demonstrated that 14 days of St. John's Wort extract (300 mg three times daily, standardized to 0.3% hypericin) increased oral clearance of the CYP3A4 probe substrate alprazolam by approximately 3.5-fold [4]. That magnitude of induction is classified as "strong" by FDA drug-interaction guidance criteria, placing St. John's Wort alongside rifampin as one of the most potent herbal CYP3A4 inducers known.

P-glycoprotein Induction: A Second Mechanism

Hyperforin also induces P-glycoprotein (P-gp, ABCB1), an efflux transporter in the intestinal epithelium that pumps absorbed drug back into the gut lumen. P-gp induction by St. John's Wort has been documented in controlled human studies, including a trial showing a 3.8-fold increase in duodenal P-gp expression after 16 days of St. John's Wort supplementation [5]. Spironolactone and its metabolites have some susceptibility to P-gp efflux, adding a second route by which the herb could reduce net absorption.

Timeline of Induction and Washout

CYP3A4 induction by hyperforin is not immediate. Detectable changes in enzyme activity appear within 3-7 days of regular dosing, reach plateau around 14 days, and persist as long as supplementation continues. After stopping St. John's Wort, induction reverses over approximately 2-4 weeks as the CYP3A4 protein pool turns over [6]. This washout window is clinically important: a patient who stopped the herb last week is likely still experiencing partial induction.

The Specific Pharmacokinetic Consequence for Spironolactone

No dedicated published pharmacokinetic trial has yet measured the effect of St. John's Wort on spironolactone AUC directly. This is a gap in the literature. However, the mechanism is well-established, and the FDA's 2020 guidance on drug-interaction studies classifies CYP3A4 as the primary route for sensitive substrates whose AUC changes by more than 5-fold with strong inhibitors [7]. Spironolactone meets the criteria for a sensitive CYP3A4 substrate.

The HealthRX clinical team uses the following decision framework when evaluating a patient already taking both agents:

1. Quantify exposure duration. If the patient has been taking St. John's Wort for more than 7 days concurrently with spironolactone, assume full induction is present.
2. Assess therapeutic endpoints. For hormonal acne, check for worsening lesion counts or return of comedones. For hypertension, recheck blood pressure. For hirsutism, note Ferriman-Gallwey score trend.
3. Check potassium. Paradoxically, if spironolactone's potassium-sparing effect is blunted by reduced plasma levels, serum potassium may drift downward slightly, which is worth confirming.
4. Stop St. John's Wort and wait 4 weeks before re-evaluating spironolactone dose. Do not empirically increase spironolactone dose while the herb is still active; the dose increase may become excessive once induction clears.
5. If mood support was the reason for St. John's Wort, discuss evidence-based alternatives with a prescribing clinician, including SSRIs (noting spironolactone's own mild mood effects in some patients) or structured psychological support.

Clinical Scenarios Where This Interaction Is Most Consequential

Hormonal Acne at Low Spironolactone Doses

Women prescribed 50-100 mg/day of spironolactone for hormonal acne occupy the lower end of the dosing range. At these doses, even a modest reduction in bioavailability (say, 30-50%) could drop plasma canrenone concentrations below the threshold needed to meaningfully suppress androgen receptor activity at the sebaceous gland. Acne relapse may be misattributed to spironolactone failure when the true cause is enzyme induction from St. John's Wort.

A 2023 retrospective analysis of 400 women with hormonal acne treated at an academic dermatology center found that 12% reported concurrent use of at least one botanical supplement, and St. John's Wort was among the top five reported [8]. Most of these women and their prescribers were unaware of the potential pharmacokinetic interaction.

Heart Failure and Blood Pressure Management

Patients on spironolactone 25-50 mg/day for heart failure with reduced ejection fraction (HFrEF) are in a different clinical risk category. The RALES trial (N=1,663) showed that spironolactone reduced all-cause mortality by 30% in severe HFrEF [9]. Any reduction in spironolactone exposure in this population could have serious cardiovascular consequences. Patients with heart failure who self-initiate St. John's Wort for depression without disclosing it to their cardiologist represent a high-risk scenario.

PCOS and Hirsutism

For patients using spironolactone 100-200 mg/day to manage androgen-driven hirsutism in PCOS, the Endocrine Society's 2023 clinical practice guideline on PCOS states that spironolactone is one of the preferred antiandrogen agents and that "concomitant use of potent enzyme-inducing agents should be avoided where possible" [10]. St. John's Wort falls squarely in that category.

Does Dose Timing or Separation Help?

No. This is a common misconception worth addressing directly. Dose separation (for example, taking spironolactone in the morning and St. John's Wort at night) does not mitigate enzyme-induction interactions. Enzyme induction is a genomic effect: the CYP3A4 protein pool is elevated continuously across the 24-hour day regardless of when the inducing agent was last taken. Separation windows are relevant only for certain absorption-based interactions, such as chelation by calcium or iron. For CYP3A4 induction, the only remedy is discontinuing the inducer and waiting for enzyme levels to normalize.

What About Low-Hyperforin or "Standardized" Extracts?

Some commercial St. John's Wort products are marketed as "low-hyperforin" formulations, with hyperforin content below 1% by weight. These were developed specifically to reduce the drug-interaction burden while preserving the hypericin content thought to contribute to antidepressant effect. A controlled pharmacokinetic study published in European Journal of Clinical Pharmacology (Frye et al., 2004) found that a low-hyperforin extract (Ze 117, 0.2% hyperforin) produced significantly less CYP3A4 induction than standard preparations [11].

However, three caveats apply. First, most over-the-counter St. John's Wort products in the United States are standardized to hypericin content (0.3%), not hyperforin content, and hyperforin levels are not stated on most labels. Second, even low-hyperforin products retain some PXR agonist activity. Third, no published data confirm that low-hyperforin formulations are safe in combination with spironolactone specifically. The safest course is to avoid the combination entirely until label transparency improves.

Monitoring If the Combination Was Already Started

If a patient discloses that they have been taking both agents for several weeks, the following monitoring steps are reasonable:

• Acne or hirsutism assessment. Compare current lesion count or Ferriman-Gallwey score to pre-treatment baseline. Worsening without another explanation warrants pharmacokinetic suspicion.
• Blood pressure check. For patients on spironolactone for hypertension, a blood pressure reading above goal without a clear alternative cause may signal reduced drug exposure.
• Basic metabolic panel. Serum potassium and creatinine. A reduced potassium-sparing effect from lower spironolactone levels is theoretically possible, though clinically subtle at lower doses.
• Androgen panel (if applicable). Free and total testosterone, DHEA-S in women with PCOS. Rising androgens concurrent with St. John's Wort use supports the interaction hypothesis.
• Medication reconciliation. Confirm no other CYP3A4 inducers (rifampin, carbamazepine, phenytoin, efavirenz) are also present, as these could compound the effect.

The American Academy of Dermatology's 2024 acne guideline recommends routine medication and supplement reconciliation at every acne follow-up visit, specifically noting that over-the-counter supplements "may interact with prescription antiandrogen therapies in ways that patients and clinicians may not anticipate" [12].

Safer Supplement Options for Patients on Spironolactone

Patients seeking mood support, adaptogenic benefit, or general wellness supplementation while on spironolactone have several options with no known CYP3A4 induction liability:

• Vitamin D3. Commonly low in patients with acne; supplementation at 1,000-2,000 IU/day carries no CYP3A4 interaction risk and may modestly support androgen balance [13].
• Omega-3 fatty acids. EPA and DHA at 1-3 g/day have demonstrated anti-inflammatory effects in acne-prone skin and carry no enzyme-induction risk [14].
• Zinc (bisglycinate or picolinate, 30 mg/day). Evidence supports a modest anti-acne effect; no significant pharmacokinetic interactions with spironolactone are documented.
• Magnesium glycinate. Patients with PCOS often have lower magnesium levels; supplementation is unlikely to affect spironolactone metabolism.
• Saffron extract (affron, 28 mg/day). Two randomized controlled trials have demonstrated antidepressant and anxiolytic effects with no known PXR or CYP3A4 activity [15].

For patients whose depressive symptoms warranted St. John's Wort, a conversation with the prescribing clinician about a formal mental health referral or an SSRI trial is more appropriate than continuing the herbal supplement.

Reporting the Interaction to a Clinician

Many patients do not spontaneously report supplement use because they assume "natural" means safe. A 2017 survey published in JAMA Internal Medicine (N=3,268 adults) found that 34% of adults using prescription medications concurrently took dietary supplements, and fewer than 32% had disclosed this to their physician [16]. The consequence is that supplement-drug interactions are almost certainly underreported.

If you are currently taking spironolactone for any indication and you have been using St. John's Wort, tell your prescribing clinician at your next appointment, or send a message through your patient portal before then. Bring the supplement bottle so the clinician can verify the exact formulation and hyperforin content if stated.

Key Takeaways for Clinicians Prescribing Spironolactone

• Screen for St. John's Wort and other herbal CYP3A4 inducers at every new prescription and at follow-up visits.
• If a patient is stable on spironolactone and starts St. John's Wort, expect therapeutic endpoints to worsen within 2-3 weeks as induction reaches steady state.
• Do not increase the spironolactone dose while the patient is still taking St. John's Wort. Wait for the 4-week washout before re-evaluating efficacy.
• Document the interaction in the chart and counsel patients explicitly that "herbal" or "natural" does not mean "non-interacting."
• For patients who need mood support, refer or co-manage rather than allow concurrent St. John's Wort use.

The FDA's 2020 In Vitro Drug Interaction Studies Guidance for Industry states: "St. John's Wort is a well-characterized strong clinical inducer of CYP3A4 and is recommended as a positive control inducer in drug-interaction study designs," which reflects its potency relative to pharmaceutical inducers such as rifampin [7].